AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results. The company ...

Dave Fredrickson of AstraZeneca highlighted that the approval of Calquence provides nearly one and a half years of additional disease progression-free time for patients, affirming its potential as ...

Recommendation based on ECHO Phase III trial results which demonstrated over 16 months of progression-free survival improvement vs. chemoimmunotherapy alone AstraZeneca’s Calquence (acalabrutinib) in ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

AstraZeneca’s (AZN) Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for the treatment of adult patients with previously ...

Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European Union for adult patients with previously untreated ...

(Sharecast News) - AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi and Calquence, marking ...

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, emphasized the potential of Calquence to transform the standard of care for MCL patients in Europe. MCL is a rare ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a prominent pharmaceutical company with a market capitalization of $225 billion and an impressive gross profit margin of 82%, has reached a significant ...